← Founder Notes
Archive

The ai-designed drug just entered the last test. insilico medicine's rentosertib, built end to end…

Yethikrishna ROriginal on Threads

the ai-designed drug just entered the last test. insilico medicine's rentosertib, built end to end by generative ai, moved into phase iii trials for the lung-scarring disease ipf this month.

the molecule's graduation day is now a matter of time.

Context

Insilico Medicine announced that the first patient was dosed in GENESIS-IPF-3 (NCT07687459), a 320-patient Phase III trial of rentosertib, a TNIK inhibitor for idiopathic pulmonary fibrosis. Coverage dated September 24 calls it the first Phase III trial of a generative-AI-discovered drug.

AI Industry Today, on October 8, notes the trial runs 52 weeks and has to determine whether the AI-designed molecule works.

How it compares

Phase III for IPF, rentosertib and the first-of-its-kind framing match Insilico's announcement and coverage. The first dosing was reported on September 24, so 'this month' is September, not October.

'End to end by generative AI' is supported by AI Industry Today, which says AI prioritized TNIK and designed the molecule.

'Graduation day is a matter of time' is the author's opinion. A Phase III trial has not reported results in the pages read.

Related work

Watch next

  • Watch for the trial's readout timeline.

Sources

  1. Rare Disease Advisor, Sep 24, 2026rarediseaseadvisor.com
  2. Ai Data News, Sep 24, 2026aidatanews.com
  3. AI Industry Today, Oct 8, 2026aiindustrytoday.com

Provenance

The note above is reproduced unedited from the original post, first published on Threads on 10 October 2026 at 06:46 IST. Sources are the papers and datasets the note draws on.

View the original post
Embed this note
<iframe src="https://founder.myndlabs.tech/notes/embed/the-ai-designed-drug-just-entered-the-last-DeS4g67DN6m" width="480" height="420" style="border:0;max-width:100%" loading="lazy" title="The ai-designed drug just entered the last test. insilico medicine's rentosertib, built end to end…"></iframe>

More notes